Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICE: Ixabepilone +/- Cetuximab in TNBC
NCT01097642Phase 2Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Oct 2008
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in triple-negative breast cancer (TNBC), sponsored by Houston Methodist Research Institute. Started Oct 2008; status: completed.
02
Drugs
KL-140
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01097642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01097642.